



WELCURE DRUGS & PHARMACEUTICALS LTD.

Regd. Off. : B-9 & 10, Laxmi Towers, L.S.C., Block C, Saraswati Vihar, Delhi -110034.
CIN No. L24232DL1996PLC227773

Date: 15th April, 2022

BSE Limited

Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai-400001

Scrip Code: 524661--Welcure Drugs & Pharmaceuticals Ltd.

Sub: Audited Financial Results for the Quarter and Financial Year ended 31.03.2022

Ref: Outcome of Board of Directors Meeting- 15th April, 2022

Respected Sir,

Pursuant to the provisions of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company in its meeting held today Friday, 15th April, 2022 at 01:30 pm and concluded at 03:00 pm, *inter-alia*, approved the Audited Financial Results of the Company for the Quarter and financial year ended 31st March, 2022.

We enclose copies of the following:

1. Audited Financial Results for the Quarter and Financial Year ended 31st March, 2022; and
2. Auditor's Report for Audited Financial Results for the said period.

Further, pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations & Disclosure Requirements) Regulation, 2015 and as amended till that date, we hereby declare and confirm that the Statutory Auditor of our Company, M/s V.P. Gupta & Co, Chartered Accountants (Firm Reg. No. 000699N), have issued Audit Report with unmodified opinion in respect of Audited Financial Results for the quarter and financial year ended 31st March, 2022.

We request you to take the same on record.

Thanking you

Yours faithfully

For Welcure Drugs & Pharmaceuticals Limited

(Mitashi Bisaria)

Director & Company Secretary

DIN: 08660802



Encl.: a/a



V.P. Gupta & Co.

Chartered Accountants

INDEPENDENT AUDITOR'S REPORT

Auditor's Report on Quarterly Financial Results and Year Ended Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

**To
Board of Directors of
Welcure Drugs & Pharmaceuticals Limited**

1. We have audited the financial results of Welcure Drugs & Pharmaceuticals Limited ("the Company") for the quarter and the year to date results for the period ended 31st March, 2022 (the "Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations.

These financial results have been prepared on the basis of the annual standalone financial statements, which are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial results based on our audit of such standalone financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard, prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder; as applicable and other accounting principles generally accepted in India and SEBI Circular CIR/CFD/FAC/62/2016 dated 5 July 2016.

2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.
3. In our opinion and to the best of our information that we had obtained and according to the explanations given to us, these quarterly and AS financial results as well as the year to date results:
 - i. Have been presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by circular no. CIR/CFD/FAC/62/2016 dated July 5, 2016 in this regard; and



288, Ghalib Apartments, Parwana Road, Pitampura, Delhi 110034, India

Ph. :- 91-11-27020321, 9313675636 Email:- tax@vpguptaandco.com



V.P. Gupta & Co.

Chartered Accountants

- ii. Gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the net profit including other comprehensive income and other financial information for the quarter and year ended March 31, 2022.
4. The Statement includes the results for the Quarter ended March 31, 2022 being the balancing figure between audited figures in respect of the full financial year and published year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

Our report is unmodified in respect of this matter.

Place: Delhi
Date: 15.04.2022

For V.P. Gupta & Co.
Chartered Accountants
FRN: 000699N



V.P. Gupta
CA V.P. Gupta
Partner
M No.: 080557

288, Ghalib Apartments, Parwana Road, Pitampura, Delhi 110034, India

Ph. :- 91-11-27020321, 9313675636 Email:- tax@vpguptaandco.com

WELCURE DRUGS AND PHARMACEUTICALS LTD						
Regd. Office: B-9& 10, Laxmi Towers LSC, C-Block, Saraswati Vihar, Delhi-110034						
CIN: L24232DL1996PLC227773						
Email Id: investor.welcure@gmail.com						
Statement of Audited Financial Results for the Quarter & Year ended March 31, 2022						
S. No.	Particulars	Quarter Ended			(Figures in Lakhs) Year Ended	
		31-Mar-22	31-Dec-21	31-Mar-21	31-Mar-22	31-Mar-21
		Audited	Un-Audited	Audited	Audited	Audited
I	Income					
	a) Revenue from operations	-	-	-	-	-
	b) Other Operating Income	8.25	-	5.20	10.50	13.33
	Total Income from operations (net)	8.25	-	5.20	10.50	13.33
II	Other Income	-	-	(0.04)	-	0.02
III	Total Income (I+II)	8.25	-	5.16	10.50	13.35
IV	Expenses					
	(a) Cost of raw materials consumed	-	-	-	-	-
	(b) Purchases of stock-in-trade	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-
	(d) Employee benefits expenses	0.36	0.36	0.21	1.29	0.84
	(e) Finance Cost	-	-	-	-	-
	(f) Depreciation and amortisation expense	-	-	-	-	-
	(g) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	1.19	0.22	0.97	6.85	7.00
	Total Expenses	1.55	0.58	1.18	8.14	7.84
V	Profit/ (Loss) Before Exceptional and Extraordinary Items and Tax	6.70	(0.58)	3.98	2.36	5.51
VI	Exceptional Items	-	-	-	-	-
VII	Profit/ (Loss) before extraordinary items and Tax (V-VI)	6.70	(0.58)	3.98	2.36	5.51
VIII	Extraordinary items	-	-	-	-	-
IX	Profit before tax (VII- VIII)	6.70	(0.58)	3.98	2.36	5.51
X	Tax Expenses					
	Current Tax	-	-	-	-	-
	Deferred Tax	-	-	-	-	-
XI	Profit (Loss) for the period from continuing operations (IX-X)	6.70	(0.58)	3.98	2.36	5.51
XII	Net Profit/ (Loss) from discontinuing operation (before Tax)	-	-	-	-	-
XIII	Tax Expense of discontinuing operations	-	-	-	-	-
XIV	Net Profit/ (Loss) from discontinuing operation after Tax	-	-	-	-	-
XV	Net Profit/ (Loss) for the Period (XI+XIV)	6.70	(0.58)	3.98	2.36	5.51
XVI	Share of profit / (loss) of associates	-	-	-	-	-
XVII	Share of profit / (loss) of Minority	-	-	-	-	-
XVIII	Net Profit/ (Loss) after taxes, minority interest and share of profit/(loss) of associates	6.70	(0.58)	3.98	2.36	5.51
XIX	Other Comprehensive Income	-	-	-	-	-
XX	Total Comprehensive Income for the period (XVIII+XIX)	6.70	(0.58)	3.98	2.36	5.51
XXI	Paid-up share capital (Face value of Rs.10/- per share)	1,211.86	1,211.86	1,211.86	1,211.86	1,211.86
XXII	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	(1,202.56)	(1,204.91)
XXIII	Earning Per Share (of Rs. 10/- each) (not annualised)					
	A) Basic	0.06	(0.00)	0.03	0.02	0.05
	B) Diluted					

Notes:

- The Statement of Audited Financial results for the Quarter and Year ended March 31, 2022 have been reviewed by the audit committee and approved by the Board of directors at their respective meetings held on 15.04.2022. There are no qualifications in Auditor's Report issued by the auditor.
- The financial results for the Quarter and Year ended March 31, 2022 have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- There were no investor complaints pending during the Quarter ended March 31, 2022.
- As the Company is mainly operating in one reportable business segment, hence the disclosure requirements of Indian Accounting Standard (Ind AS-108) "Operating Segment" is not applicable.
- The Previous Quarter ended figures have been re-grouped/ re-arranged, whenever necessary.
- There is no need to provide any reconciliation as required by the circular dated July 05, 2016, since there is no change in the figures due to transit from the previous Indian GAAP to Ind-AS.
- Figures of last quarters are the balancing figures between audited figures in respect of the full financial year and the published year-to-date figures upto the third Quarter of the current financial year.

For Welcure Drugs & Pharmaceuticals Limited

Place: Delhi
Date: 15.04.2022



Sudhir Chandra
Managing Director
DIN: 00323545

WELCURE DRUGS AND PHARMACEUTICALS LTD			
Regd. Office: B-9& 10, Laxmi Towers LSC, C-Block, Saraswati Vihar, Delhi-110034			
CIN: L24232DL1996PLC227773			
Email Id: investor.welcure@gmail.com			
Statement of Assets and Liabilities			
	Particulars	31-03-2022 (Audited)	(Figures in Lakhs) 31-03-2021 (Audited)
A	ASSETS		
I	Non-current assets		
	(a) Property, Plant & Equipment	-	-
	(b) Capital Work-in-Progress	-	-
	(c) Goodwill	-	-
	(d) Other Intangible Assets	-	-
	(e) Financial Assets		
	(i) Investments	-	-
	(ii) Loans	-	-
	(iii) Other Financial Assets	-	-
	(f) Other Non current Assets	3.08	2.56
	(g) Deferred Tax Assets	-	-
	Subtotal- Non-current assets	3.08	2.56
II	Current assets		
	(a) Inventories	-	-
	(b) Financial Assets		
	(i) Loans	-	-
	(ii) Cash and Cash Equivalents	6.60	4.75
	(iii) Other Bank Balances	-	-
	(iv) Trade Receivables	-	-
	(v) Other Financial Assets	-	-
	(c) Other Current Assets	-	-
	(d) Current Tax Assets	-	-
	Subtotal- Current assets	6.60	4.75
	TOTAL - ASSETS	9.68	7.30
B	EQUITY AND LIABILITIES		
I	Equity		
	(a) Equity Share Capital	1,211.86	1,211.86
	(b) Other Equity	(1,202.56)	(1,204.91)
	Subtotal- Equity	9.30	6.94
II	Liabilities		
(i)	Non-current liabilities		
	(a) Financial Liabilities	-	-
	(b) Provisions	-	-
	(c) Deferred Tax Liabilities	-	-
	(d) Other Non-Current Liabilities	-	-
	Subtotal- Non-current liabilities	-	-
(ii)	Current liabilities		
	(a) Financial Liabilities		
	(i) Loans	-	-
	(ii) Trade Payables	-	-
	(iii) Other Financial Liabilities	0.38	0.36
	(b) Other current Liabilities	-	0.00
	(c) Current Tax Liabilities	-	-
	(d) Short-term provisions	-	-
	Subtotal- Current liabilities	0.38	0.36
	TOTAL - EQUITY AND LIABILITIES	9.68	7.30

Place: Delhi
Date: 15.04.2022



For Welcure Drugs & Pharmaceuticals Limited

(Signature)
Sudhir Chandra
Managing Director
DIN:00323545

WELCURE DRUGS AND PHARMACEUTICALS LTD

Regd. Office: B-9& 10, Laxmi Towers LSC, C-Block, Saraswati Vihar, Delhi-110034

CIN: L24232DL1996PLC227773


Email Id: investor.welcure@gmail.com

Cash Flow Statement for the period ended March 31, 2022

		(Figures in Lakhs)	
Particulars		31-03-2022 (Audited)	31-03-2021 (Audited)
A. Cash Flow from Operating Activities			
Net Profit/(Loss) before tax		2.36	5.51
Operating Profit before working capital changes		2.36	5.51
Adjustments for working capital changes			
Other Assets		(0.53)	(0.62)
Other Financial Liabilities		0.02	(0.61)
Other Current Liabilities		(0.00)	(0.06)
Cash generated from operations		1.86	4.22
Net Cash flow from/(used in) Operating Activities	(A)	1.86	4.22
B. Cash Flow from Investing Activities			
Net Cash flow from Investing Activities	(B)	-	-
C. Cash Flow from Financing Activities			
Net Cash flow from Financing Activities	(C)	-	-
Net Increase/(decrease) in Cash and Cash Equivalents	(A+B+C)	1.86	4.22
Cash and Cash Equivalents(Opening Balance)		4.75	0.53
Cash and Cash Equivalents(Closing Balance)		6.60	4.75
Change in cash and cash equivalents		1.86	4.22

Place: Delhi
Date: 15.04.2022

For Welcure Drugs & Pharmaceuticals Limited


Sudhir Chandra
Managing Director
DIN:00323545